Has Corey Berlin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $741,738 in general payments to Corey Berlin, MD across 2,438 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Corey Berlin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Corey Berlin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Corey Berlin, MD

Endocrinology, Diabetes & Metabolism · Raleigh, NCNPI 1154399418

Payments from drug & device makers

$741,738in general payments, 2019–2025

Across 2,438 payments — averaging $304.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$271K
Novo Nordisk$222K
Boehringer Ingelheim$72K
Amarin Pharma, Inc.$50K
Johnson & Johnson$36K
AstraZeneca$33K
plus $58K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	567	$270,968
Novo Nordisk	430	$221,596
Boehringer Ingelheim	149	$72,239
Amarin Pharma, Inc.	120	$49,900
Johnson & Johnson	66	$35,835
AstraZeneca(2 entities)	91	$33,236
Sanofi-aventis U.S. LLC	70	$15,481
Mannkind Corporation	147	$8,487
Radius Health, Inc.	30	$6,922
Xeris Pharmaceuticals, Inc.	35	$5,722
Corcept Therapeutics	50	$3,395
Zealand Pharma US, Inc.	7	$3,014
Abbott	114	$2,383
Amgen(2 entities)	105	$1,809
Esperion Therapeutics, Inc.	49	$1,607
Dexcom, Inc.	29	$947
Insulet Corporation	23	$911
Medtronic(2 entities)	27	$875
IBSA Pharma Inc.	55	$806
AbbVie	50	$748
Antares Pharma, Inc.	24	$596
Bayer	21	$488
Cequr Corporation	4	$389
BETA Bionics, Inc.	5	$349
Kowa Pharmaceuticals America, Inc.	20	$277
Tolmar, Inc.	7	$174
Novartis	10	$171
Almatica Pharma LLC	14	$168
Merck	12	$164
Amneal Pharmaceuticals LLC	10	$157
Tandem Diabetes Care, Inc.	4	$141
Recordati_rare_diseases_inc.	6	$116
Ascendis Pharma Endocrinology Inc	6	$111
Idorsia Pharmaceuticals US Inc	1	$109
Lifescan, Inc.	6	$107
Nestle Healthcare Nutrition Inc.	5	$99
Astellas Pharma US Inc	6	$99
Senseonics, Incorporated	3	$88
Amphastar Pharmaceuticals, Inc.	5	$77
Pfizer	4	$68
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$65
Boston Scientific	2	$64
Shire North American Group Inc	4	$60
Nevro Corp.	3	$57
Clarus Therapeutics Inc.	4	$56
Verity Pharmaceuticals Inc.	3	$54
Halozyme Inc	2	$42
Kyowa Kirin, Inc.	2	$41
Rhythm Pharmaceuticals, Inc.	2	$37
EUSA Pharma (US) LLC	2	$36
Gilead	1	$31
Ultragenyx Pharmaceutical Inc.	2	$31
Intra-sana Laboratories	2	$31
Acella Pharmaceuticals, LLC	2	$29
Aimmune Therapeutics, Inc.	1	$26
Chiesi USA, Inc.	1	$25
Takeda Pharmaceuticals U.S.A., Inc.	2	$25
Arbor Pharmaceuticals, Inc.	1	$21
Companion Medical, Inc.	2	$20
Embecta Corp.	1	$20

How this compares

$741,738 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina →

Medicare billing

Part B allowed, 2024

$179,463

Medicare patients

477

Services billed

1,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Raleigh

Denis BeckerRaleigh$459K
Elizabeth HoltRaleigh$167K
Julia Warren-UlanchRaleigh$31K
Bhairavi SheshadriRaleigh$28K
Kathryn LucasMorehead City$37.9M
Mark WarrenGreenville$5M
Mary LawrenceMorehead City$4.9M
John ParkerWilmington$4.1M
John BuseChapel Hill$3.8M
Wendy LaneAsheville$1.9M

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →